Intra-Cellular Therapies Inc
ITCI
ISIN null / Valor 23194616
Intra-Cellular Therapies Inc
UMushroom community rating:
About company
Intra-Cellular Therapies, Inc. is a publicly traded (NASDAQ: ITCI) biopharmaceutical company headquartered in New York that develops and commercializes small-molecule therapies for neuropsychiatric and neurological disorders by targeting intracellular signaling pathways. The company’s lead commercial product is lumateperone (marketed as CAPLYTA), an antipsychotic approved for schizophrenia and for depressive episodes associated with bipolar disorder, and its pipeline includes additional clinical-stage programs—among them ITI‑214, a phosphodiesterase‑1 inhibitor under investigation for central nervous system and cardiovascular indications—reflecting the firm’s dual focus on advancing clinical development, obtaining regulatory approvals for new indications, and building a commercial footprint in specialty psychiatry.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
8996 M
Market cap (USD)
Daily traded volume (Shares)
84.6 / 82.43
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
